... company's stock valued at $115,000 after purchasing an additional 10,000 shares during the last quarter. Ardsley Advisory Partners increased its holdings in CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns ...
http://ift.tt/2liBsWX
No comments:
Post a Comment